logo

For the Inventor, By the Inventor

Fessenheim-le-Bas, France

Valerie B Schini-Kerth

This inventor holds 5 USPTO granted patents and 7 published patent applications. Top assignee: Pivotal Therapeutics, Inc.. Active years: 2014-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Valerie B Schini-Kerth. Retrieved from https://idiyas.com/inventor/valerie-b-schini-kerth

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

% Patents Active = 80.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal5 out of 5 
 
Pivotal Therapeutics, Inc.
 patents

Years Active: 2014-2016

Loading Chart...
5 patents (USPTO):Explore Patents
1. 9248138 - Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids (2016-02-02),
2. 9119826 - Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels (2015-09-01),
3. 8952000 - Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events (2015-02-10),
4. 8951514 - Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels (2015-02-10),
5. 8715648 - Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics (2014-05-06),

Title: **Valerie B Schini-Kerth: Innovator in Cardiovascular Health**

Introduction

Valerie B Schini-Kerth is a prominent inventor residing in Fessenheim-le-Bas, France. With five patents to her name, she has made significant contributions to the field of cardiovascular health through her innovative approaches and formulations.

Latest Patents

Among her notable inventions, Valerie's latest patents include a groundbreaking process and composition designed for the stabilization of vulnerable plaque. This innovation utilizes a combination of statins and omega-3 fatty acids, aimed at mitigating omega-3 deficiencies in individuals prone to cardiovascular diseases. The composition consists of a specific ratio of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA), and Docosahexaenoic acid (DHA), formulated to ensure that 92% of the total omega-3 content effectively stabilizes vulnerable plaque. Additionally, she developed a comprehensive kit for dietary management, specifically tailored for cardiovascular patients suffering from deficiencies in blood EPA and DHA levels. This kit not only includes a diagnostic assay but also a pharmaceutical-grade omega-3 fatty acid formulation, further emphasizing her commitment to enhancing patient care.

Career Highlights

Valerie B Schini-Kerth is associated with Pivotal Therapeutics, Inc., where she focuses on the research and development of innovative therapeutic solutions. Her extensive experience and expertise in the pharmaceutical sector have positioned her as a leading figure in her field.

Collaborations

Throughout her career, Valerie has collaborated with esteemed colleagues such as George Jackowski and Rachelle MacSweeney. These partnerships have enriched her work, allowing for a multidisciplinary approach to addressing complex health issues, particularly in cardiovascular health.

Conclusion

Valerie B Schini-Kerth stands out as a vital contributor to the field of cardiovascular health through her inventive spirit and dedication to improving patient outcomes. Her innovative work continues to pave the way for advancements in medical treatments and dietary management of cardiovascular diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…